Urticaria : diagnosis and management by Aquilina, Susan
Issue 22  20168          Journal of the Malta College of Pharmacy Practice
Consultant Dermatologist, 
Department of Dermatology and Venereology, Sir Paul Boffa Hospital, Floriana, Malta 
Email: sue_aquilina@yahoo.com
Key words
Urticaria, angioedema, oral antihistamines, omalizumab
Susan Aquilina MD, FRCP (UK)
Abstract
Urticaria is a common and characteristic skin condition presenting 
with wheals and/or angioedema. It may be acute or chronic and has 
various causes and triggers. Patients with urticaria are often referred 
to allergy clinics to find out ‘what they are allergic to’. Urticaria may 
impact significantly on a patient’s quality of life. Its management 
involves identifying and removing causes or triggers, together with 
oral antihistamines as first line treatment for symptomatic control. 
Omalizumab is a recently licensed expensive treatment option for 
patients with urticaria resistant to oral antihistamines, and has 




•	 To make a more confident clinical diagnosis of urticaria
•	 To increase familiarity with the commonest causes and triggers of urticaria 
•	 To update the knowledge on management of urticaria
Introduction
Urticaria, also known as ‘nettle rash’ or 
‘hives’, is a reaction pattern that gets its 
name from the Latin word for nettle (urtica). 
The nettle is a weed with stinging hairs that 
causes contact urticaria. Urticaria describes a 
reaction pattern with characteristic features 
and may have many causes or triggers. It 
is described as acute if it lasts less than 
6 weeks, or chronic if it lasts 6 weeks or 
longer. Some patients have episodic acute 
intermittent urticaria lasting for hours or 
days and recurring over months or years. 
Urticaria is a very common condition, 
occurring across all age ranges. It has a 
lifetime prevalence of approximately 20% 
in the general population. The chronic form 
affects 1-3% of the population.1 When 
severe and extensive, it often prompts 
patients to seek treatment in the emergency 
department; in fact, it is the most common 
skin disease treated in the emergency 
department. Patients with urticaria may also 
seek advice from their pharmacist. Most 
new-onset urticaria resolves spontaneously 
within days or a few weeks. However, at 
least 20% of chronic urticaria patients with 
symptoms severe enough to warrant hospital 
referral remain symptomatic 10 years after 
first presentation.2 Although rarely life-
threatening, chronic urticaria leads to 
both misery and embarrassment and has a 
significant impact on an individual’s quality 
of life.3 
Box 1 summarizes the main clinical 
features of urticaria.4-6 It is typical of 
patients with urticaria to have no evident 
lesions at the time of their doctor’s visit. In 
this situation, a good history is sufficient to 
make the diagnosis. Patients may also bring 
photos of their rash to the clinic.   
The characteristic urticarial wheals 
affect the superficial skin layers (papillary 
dermis). When the submucosa, the deeper 
reticular dermis and subcutaneous tissues 
are involved, the resulting deep swelling 
is called angioedema. This is often most 
notable in the eyelids and lips. These 
swellings can be painful rather than itchy. 
Urticarial wheals and angioedema often 
coexist, but either can occur separately. 
Unlike wheals that individually resolve within 
24 hours, angioedematous swellings can 
persist for a few days. Disfiguring when they 
occur in the skin, they can be extremely 
alarming and occasionally life-threatening 
when they occur in the oropharynx.
Urticaria needs to be differentiated 
from other medical conditions where 
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wheals, angioedema, or both can occur as 
a symptom, for example skin prick test, 
anaphylaxis, or hereditary angioedema.
Pathogenesis
The mast cell is the primary agent in 
the pathogenesis of urticaria. Mast cell 
stimulation results in the release of both 
preformed (histamine) and newly formed 
mediators (prostaglandins) from cytoplasmic 
granules, which cause wheal formation, 
vasodilatation, oedema (due to increased 
microvascular permeability) and erythema. 
Mast cells release chemoattractants for 
other cells (for example eosinophils and 
neutrophils) that are also involved in wheal 
formation. A number of agents may be 
involved in the pathogenesis of urticaria, 
which may explain why antihistamines are 
not always effective therapy.7 
Release of mediators by mast cells may 
be caused by both immune and nonimmune 
mechanisms. All mast cells express high-
affinity IgE receptors (FceRIs) that enable 
their involvement in IgE-dependent allergic 
reactions. When IgE forms a complex with 
FceRI on the mast cell to which an allergen 
binds, degranulation occurs. Examples of 
IgE-mediated urticaria include acute urticaria 
secondary to foods (for example peanuts, 
eggs, shellfish), animal dander, stinging 
insects, some medications (for example beta-
lactam antibiotics) and latex. 
Mast cell degranulation also occurs 
through a variety of other mechanisms. Some 
agents, such as opioids and radiocontrast 
media, cause mast cell degranulation directly 
through nonimmunologic means. In chronic 
spontaneous urticaria (CsU, previously called 
chronic idiopathic urticaria), there appears 
to be persistent activation of mast cells 
in the skin, but the precise mechanism is 
unknown. Functional auto-antibodies against 
the FceR1 on the mast cell surface have been 
demonstrated in 30–40% of patients with 
chronic urticaria suggesting an autoimmune 
basis. This variant of chronic urticaria is 
described as chronic autoimmune urticaria 
(CaU). Patients with CaU tend to follow a 
more aggressive course and often require 
more aggressive therapy.8  
The commonest type of angioedema 
without wheals is histaminergic.
Angioedema without wheals is a cardinal 
feature of hereditary angioedema (HAE), 
which is bradykinin-mediated and typically 
involves subcutaneous sites, gut and larynx. 
In Types I and II HAE, levels of C4 and C1 
inhibitor (functional and/or antigenic) are 
low.9
Commonest causes and triggers of 
urticaria and angioedema
Acute urticaria
A definitive inciting agent can be identified 
in about 50% of cases of acute urticaria 
and angioedema. Infections, medications 
and food were identified as the commonest 
causes.4 Acute urticaria is considered to be 
a classical manifestation of viral infection 
in general, especially in children, but also 
in adults.10 When the trigger is a viral upper 
respiratory tract infection (URTI), the patient 
should be informed of the self-limiting 
duration of the disorder. Other viruses (for 
example hepatitis or herpes viruses) or 
infections (including streptococcal infections 
and chronic parasitic infections) may also be 
possible triggers.
Drug triggers
Acute urticarial reactions from drugs 
are common. The commonest drugs to 
trigger urticaria are nonsteroidal anti-
inflammatory drugs (NSAIDs), salicylates, 
codeine and antibiotics, especially 
penicillins, cephalosporins, tetracyclines and 
sulphonamides. Urticaria usually comes on 
within a few hours of exposure to the drug. 
A notable exception is angioedema secondary 
to angiotensin converting enzyme (ACE) 
inhibitors (refer to Box 2).5
Box 1: Clinical features of urticaria
•	 Pink, non-scaly, itchy or sometimes burning swellings (wheals) that can occur 
anywhere on the body and blanche with pressure.
•	 Lesions of urticaria can be polymorphic and vary from several millimetres to large, 
continuous plaques.
•	 Individual wheals do not last longer than 24 hours, fading without a trace and 
without scars, but new wheals may continue to appear for days, months or even 
years.
•	 Patients with urticaria tend to rub their skin rather than scratch, so heavily scratched 
skin is rarely, if ever, a consequence of urticaria.
•	 Patients show no or minimal systemic symptoms. Patients often feel fatigued, 
especially during relapses, but headache, dizziness, syncope, or respiratory, 
gastrointestinal or arthralgic symptoms are rare.
Box 2: Angiotensin converting enzyme (ACE) inhibitor-induced angioedema
•	 ACE inhibitors can cause angioedema without wheals resulting in airway compromise. 
The patient usually presents with swelling of the tongue, but the lips, pharynx, larynx 
and viscera may also be involved. 
•	 Fatalities are reported and, hence, it is mandatory to recommend that the ACE 
inhibitor is withdrawn.
•	 ACE inhibitors are contraindicated in individuals with a history of angioedema with or 
without wheals. 
•	 The mechanism underlying the angioedema is likely to be due to the reduced 
metabolism of bradykinin. 
•	 Angioedema associated with angiotensin receptor blockers has been occasionally 
reported and hence their use in individuals with ACE inhibitor-related angioedema 
has been questioned but is not contraindicated.
•	 The incidence of ACE inhibitor-induced angioedema may be as high as 0.68%.
•	 Most cases were initially thought to occur in the first weeks of treatment, but it 
is now appreciated that later onset angioedema, occurring after many years of 
uneventful drug use, is quite common. 
•	 The episodes of angioedema may persist for several months after withdrawal of the 
ACE inhibitor without undermining the validity of the drug-related diagnosis. 
•	 Individuals who do not improve even after several months of stopping the ACE 
inhibitor are likely to have an alternative explanation for their angioedema and were 
coincidentally taking an ACE inhibitor. 
•	 There are no routine investigations to distinguish responders from non-responders to 
ACE inhibitor withdrawal. If the ACE inhibitor is responsible but is not withdrawn, the 
attacks may become more severe and frequent.
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Food triggers
Acute urticarial reactions to food are 
believed to be common and many go 
unreported. Food allergy should be 
considered in acute urticaria and urticaria 
in children. Such foods as tree nuts, 
peanuts, eggs, shellfish, and tomatoes 
should be considered (the involvement 
of food additives or preservatives is 
controversial). Urticarial reactions may 
not be to the basic nutrient but to other 
constituents such as spices. Usually, 
reactions occur within minutes or a few 
hours but sometimes allergic urticaria 
develops many hours after food ingestion. 
This may occur due to slow absorption 
or metabolism of food, or because the 
mechanism is IgG-mediated. Urticaria 
occurs consistently after every exposure 
to the problem food. A careful history 
is normally adequate to determine if a 
particular food is causing urticaria in a 
patient. Testing for serum IgE to the food 
is occasionally performed to help confirm a 
clinical suspicion. Rarely, allergic reactions 
to food may occur only if intake is followed 
by exercise, with neither the food nor 
exercise alone inducing wheals. Substances 
reported to cause this include wheat, 
hazelnuts and shellfish. Box 3 summarizes 




Most cases of chronic urticaria are 
thought to have an autoimmune origin. 
Autoimmune conditions (including thyroid 
disease, vitiligo, insulin-dependent 
diabetes, rheumatoid arthritis, and 
pernicious anaemia) are associated more 
frequently with chronic urticaria patients 
having functional autoantibodies than in 
those without autoantibodies. URTI and 
psychological factors, including stressful 
events, are thought to aggravate chronic 
urticaria. Rarely is food allergy the cause 
of chronic urticaria and food can typically 
be excluded on the basis of the clinical 
history. Alcohol can aggravate chronic 
urticaria by its effect of vasodilation.5
Inducible urticarias 
Inducible urticarias are responsible for 
approximately 20-30% of cases of chronic 
urticaria. In some patients, the triggering 
stimuli are the predominant cause of 
the condition, whereas in other patients 
it is an incidental factor in a case of 
chronic urticaria. Inducible urticarias are 
reproducible with the appropriate stimuli 
and can be identified with a thorough 
history and sometimes challenge testing. 
In many patients, the condition gradually 
improves and clears after several years, for 
example after 2-3 years, but the duration is 
usually quite unpredictable.11
•	 Patients with symptomatic 
dermographism (writing on the skin) 
can be diagnosed in an office setting 
by stroking the skin with a firm object, 
such as a tongue depressor. This action 
provokes a typical, itchy, wheal-and-
flare response within a few minutes, 
usually resolving within an hour.
•	 Patients with cholinergic urticaria 
get numerous small pruritic wheals 
after sweating, for example following 
exercise or emotion. 
•	 Patients with delayed pressure urticaria 
(DPU) suffer from erythema and 
swelling, associated with itch and/
or pain, typically 4-6 hours after a 
pressure stimulus.
•	 Examples of pressure stimuli 
include standing, walking, 
sitting on a hard surface, using 
tools (such as a screwdriver 
or a hammer), hand-clapping, 
carrying a handbag or wearing 
tight-fitting clothes, especially at 
the waistline. Patients with DPU 
may be significantly limited in 
activities of daily life.
•	 Lesions can occur anywhere, 
but are especially common on 
the hands and feet. They may 
persist for three days and may 
be associated with flu-like 
symptoms. 
•	 Patients with cold urticaria develop 
an urticarial rash and/or angioedema 
within 2-5 minutes of being exposed 
to cold, cold water, cold wind and 
cold objects. Symptoms usually last 
for a few hours. In very severe cases, 
hypotension, shock, collapse and even 
death may occur, often after swimming 
in cold water. 
•	 Cold urticaria may be primary 
(idiopathic) or secondary to an 
underlying haematologic (for 
example cryoglobulinaemia or 
chronic lymphocytic leukaemia) 
or infectious disease (for example 
varicella or glandular fever); most 
cases are idiopathic. 
•	 Contact urticaria refers to the onset 
of urticaria within 30-60 minutes of 
contact with an inciting agent, for 
example latex, plants (including the 
stinging nettle), animals (caterpillars, 
dander), medications and food (for 
example fish, garlic, onions, tomato). 
•	 Other forms of inducible urticaria 
include aquagenic urticaria, vibratory 
urticaria and solar urticaria. 
Some conditions that may  
be confused with urticaria
•	 Arthropod bites. Pruritic papules and 
papulovesicles with a central punctum  
appear on exposed skin and usually 
take more than 24 hours to resolve. 
Sometimes arthropod bites trigger a 
hypersensitivity reaction called papular 
urticaria. In this case, the itchy red 
papules can come up even under tight 
clothes, in areas away from the bites.
•	 Polymorphic light eruption (PLE). This 
is a reaction to the sun, coming up 
after minutes or hours of sun exposure, 
typically on skin that is having its 
first exposure to the spring or summer 
sun.  Lesions last for several days. PLE 
usually becomes less of a problem as 
the summer progresses, as the skin gets 
‘hardened’ to the sun.  PLE is much 
commoner than solar urticaria, in which 
wheals develop within 5-10 minutes of 
sun exposure and usually resolve within 
an hour.
•	 Urticarial vasculitis. In this variant of 
vasculitis, lesions look like urticarial 
wheals, but they burn rather than 
itch, last longer than 24 hours and 
tend to leave a bruise-like stain on 
fading. Urticarial vasculitis is usually 
confirmed by taking a skin biopsy and 
is investigated as for other forms of 
vasculitis. 
Box 3: IgE-mediated food-induced urticaria/angioedema
•	 Symptoms typically occur reproducibly within 60 min of exposure to the offending 
food rather than coming on overnight or being present first thing in the morning.
•	 Symptoms do not last several days. 
•	 Additional symptoms are usually present, such as oropharyngeal itching and 
discomfort, wheezing, vomiting or abdominal pain.
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•	 Scombroid food poisoning. This is a 
foodborne illness that results from 
eating spoiled (decayed) fish, especially 
mackerel, tuna, bluefish, mahi-mahi, 
bonito, sardines, anchovies, and related 
species of fish that were inadequately 
refrigerated or preserved after being 
caught. It resembles an allergic reaction, 
but is actually due to histidine that 
exists naturally in many types of fish, 
which is broken down by bacteria into 
histamine at temperatures above 16°C. 
Histamine is not destroyed by normal 
cooking temperatures, so even properly 
cooked fish can be affected. Symptoms 
consist of skin flushing (especially of 
the face, spreading to the torso), facial 
sweating, throbbing headache, burning-
peppery taste sensations in the mouth 
and throat, abdominal cramps, nausea, 
diarrhoea, palpitations, a sense of 
unease, and, rarely, collapse or loss of 
vision. Symptoms usually occur within 
10–30 minutes of ingesting the fish and 
are generally self-limited, but respond 
quickly to oral antihistamines.12 
Clinical history and examination
A detailed history in a patient with urticaria 
and/or angioedema is essential. Note should 
be made of the nature, site and duration of 
individual wheals, and whether they are itchy 
or painful. The circumstances of onset and 
any triggers should be noted, together with 
the frequency and pattern of recurrence. A 
family history and detailed drug history are 
important, as well as response to previously 
attempted treatments. The clinical history 
often identifies relevant triggers and directs 
any further investigations. 
Laboratory investigations
The diagnosis is based primarily on 
the clinical presentation. The need for 
investigations to elucidate a possible 
underlying cause should be guided by the 
history, but may not be necessary in patients 
showing a good response to antihistamines. 
Complete blood count (CBC) and erythrocyte 
sedimentation rate (ESR) or C-reactive protein 
(CRP) are often performed routinely in 
patients with chronic urticaria.6
In patients with angioedema without 
urticaria, and who are not on ACE inhibitors, 
it is important to rule out C1 esterase 
inhibitor deficiency. A normal plasma C4 
during an attack or normal C4, C1 inhibitor, 
and C1 inhibitor function between attacks, 
will typically exclude this.5
Management 
In patients with acute urticaria and 
associated shortness of breath, suggesting 
respiratory involvement and a diagnosis 
of angioedema, the patient should be 
monitored in the emergency department 
until normal airway function is restored. 
Adrenaline should be used when laryngeal 
angioedema is suspected.
An adrenaline autoinjector is rarely 
required and should only be considered if 
there is a history of significant angioedema 
affecting the upper airway (rare in 
angioedema with urticaria). The patient 
should then be shown how to use the 
device and provided with a written self-
management protocol. For patients with a 
known history of hereditary angioedema, 
C1 esterase inhibitor concentrate, 
ecallantide, or icatibant should be 
administered as soon as an angioedema 
attack is recognized.
Acute urticaria restricted to the skin 
and chronic urticaria do not require 
hospitalization and can be managed 
with outpatient care. Inpatient care for 
angioedema is usually not necessary when 
timely treatment is administered.5,6 
General measures
Any triggering foods or drugs identified 
from the history should be withdrawn. 
Aggravating factors such as heat, tight 
clothing, stress, overtiredness and alcohol, 
as well as trigger stimuli for physical 
urticaria should be avoided if possible. It is 
important to reassure anxious patients that 
the eruption is not a hallmark of cancer, 
HIV infection or other underlying disease.
Certain medications, such as aspirin 
and NSAIDS, are reported to exacerbate 
urticaria in patients with chronic urticaria 
resulting from other causes.  Their 
avoidance in favour of paracetamol as an 
analgesic should usually be recommended 
because these drugs aggravate chronic 
urticaria in about 30% of patients.  
Patients taking low-dose aspirin for its 
antithrombotic properties can usually 
continue regular treatment, although non-
aspirin alternatives, such as clopidogrel, 
are available. It is good practice to 
recommend avoidance of codeine and 
other opiates in view of the enhanced 
skin test reactions to codeine found in 
chronic urticaria, but the value of this is 
unclear. It is common to see exacerbations 
of chronic urticaria at the time of minor 
viral infections, and it may be difficult 
to differentiate between a flare caused by 
the illness and a flare caused by medication 
taken for it.5,6 
Oral antihistamines 
Oral antihistamines active against the H1 
receptor remain the mainstay of treatment 
in patients with urticaria, providing 
control of symptoms.3,4 There are several 
on the market. First-generation (sedating) 
antihistamines and their recommended 
adult doses include chlorphenamine 
(4mg every 4-6 hours), diphenhydramine 
(25-50mg every 4-6 hours), hydroxyzine 
(25-100mg daily) and promethazine (25mg 
nocte). Second-generation (non-sedating 
or minimally sedating) antihistamines with 
their licensed adult doses include acrivastine 
(8mg, 1-3 times a day), bilastine (20mg 
daily), cetirizine (10mg daily), desloratadine 
(5mg daily), fexofenadine (180mg daily), 
levocetirizine (5mg daily), loratadine 
(10mg daily), mizolastine (10mg daily) and 
rupatadine (10mg daily). 
Individual patient responses and side-
effects to antihistamines vary. Due to the 
absence of head-to-head comparisons in 
clinical trials, none can be recommended 
over others, but non-sedating or minimally 
sedating antihistamines are generally 
preferred. The older first-generation 
sedating antihistamines have pronounced 
anticholinergic effects and sedative actions 
on the central nervous system, which 
last longer than 12 hours, whereas the 
antipruritic effects last only for 4-6 hours. 
Many interactions have been described for 
these sedating antihistamines with alcohol 
and drugs affecting the central nervous 
system. They can also interfere with rapid 
eye movement sleep and impact on learning 
and performance.13 
It is recommended that modern second-
generation H1-antihistamines are to be 
used as first-line treatment of urticaria 
because of their good safety profile.
 
The usual once-daily dose may be increased 
incrementally in resistant cases up to 3-4 
times the recommended dose (off-label). 
Updosing with a single antihistamine 
is preferable to mixing different 
antihistamines. Patients should be advised 
that antihistamines work best when they are 
taken regularly.14 In patients with chronic 
urticaria, treatment for 6 or even 12 months 
is advised, with gradual withdrawal over a 
period of weeks. Safety data is available for 
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oral antihistamines taken continuously for 
several years. For patients with infrequent 
symptoms, treatment may be taken as 
required or even prophylactically (for 
example prior to an important event such 
as a wedding or a work presentation). 
A trial of up to fourfold dose of modern 
second-generation H1-antihistamines 
is recommended as second-line in the 
algorithm of treatment.
Box 4 summarizes the use of oral 
antihistamines in children, while Box 5 
indicates the recommended antihistamines 
in pregnancy and during breast-feeding.5
Treatment in resistant cases
Oral corticosteroids may occasionally 
be required in short rescue courses for 
angioedema affecting the mouth or for 
severe exacerbations of chronic urticaria 
that have not responded to full-dose 
antihistamines. Examples are 30-40 mg of 
prednisolone daily for 1-3 days reducing 
to zero over 10 days, or 30-40 mg daily for 
3-7 days. Prolonged daily treatment with 
oral corticosteroids nearly always leads 
to severe systemic toxicity accompanied 
by poor control of urticaria and severe 
rebound on attempts to withdraw.5,6 
Third-line treatment for resistant 
cases includes cyclosporine, montelukast 
and omalizumab. Efficacy of ciclosporin 
A in combination with a modern second-
generation H1-antihistamine has been 
shown in placebo-controlled trials as well 
as open controlled trials. This drug does 
have a high incidence of adverse effects, 
but it has a far better risk/benefit ratio 
than long-term use of oral corticosteroids. 
Anti-leukotrienes such as montelukast 
may be useful in urticaria patients who 
are sensitive to aspirin. Omalizumab is a 
recently licensed humanized monoclonal 
anti-IgE antibody indicated in patients 
with spontaneous and autoimmune chronic 
urticaria who have persistent symptoms 
despite high-dose antihistamines. It is 
expensive and requires monthly injections 
but appears well-tolerated. It is effective 
in approximately 80% of individuals with 
persistent and resistant symptoms, leading 
to a rapid improvement. Currently, treatment 
Box 5: Oral antihistamines in pregnancy and breastfeeding
•	 If an antihistamine is required in pregnancy, the lowest dose of loratadine, cetirizine 
or chlorphenamine should be used. Loratadine and cetirizine have been assigned 
a category B by the US FDA. Hydroxyzine is specifically contraindicated in early 
pregnancy.
•	 If an antihistamine is required during breastfeeding, it is recommended that 
either cetirizine or loratadine are taken at the lowest dose. Whenever possible, 
chlorphenamine should be avoided during breastfeeding as it may cause drowsiness 
and poor feeding.
is recommended for 6 months, but 
typically relapses occur when treatment 
is discontinued.15,16 Figure 1 illustrates 
the EAACI/GA2LEN/EDF/WAO (2013 
revision and update) recommended 
treatment algorithm for urticaria.6
Some other (off-label) treatment 
options for resistant cases include 
dapsone, mycophenolate mofetil and 
methotrexate. Tranexamic acid may 
benefit patients with antihistamine-
resistant angioedema without wheals. 
Due to the migrating nature of urticarial 
wheals, topical steroids are not indicated. 
Cooling antipruritic lotions such as 2% 
menthol in aqueous cream can, however, 
be soothing. 
Conclusion
In patients with urticaria, the history 
and physical examination are crucial 
while undirected laboratory examination 
is typically fruitless. Although acute 
urticaria often has an identifiable 
trigger (foods, drugs, virus), chronic 
urticaria frustratingly tends to remain 
idiopathic. About 30–40% of patients 
with chronic idiopathic disease appear to 
have an autoimmune aetiology. Second-
generation H1 receptor antihistamines 
represent the first-line therapy for 
urticaria. 
Key points
•	 A diagnosis of urticaria is usually easily made from the clinical history
•	 Triggers and aggravating factors can often be elicited by taking a good history 
without the need for testing 
•	 Any potential triggers or aggravating factors should be removed where possible
•	 Modern second-generation oral antihistamines are indicated as first-line treatment 
in patients with urticaria, with updosing if necessary
•	 Omalizumab (anti-IgE) is a new treatment option in patients who do not respond to 
oral antihistamines or second-line treatment options
Box 4: Oral antihistamines in children
•	 Cetirizine and desloratadine are licensed for the treatment of chronic urticaria in 
children from 1 year of age.
•	 Loratadine and levocetirizine are licensed for the treatment of children 2 years and 
older. 
•	 Acrivastine, bilastine, fexofenadine, mizolastine and rupatadine are licensed for use 
in children over 12 years. 
•	 Desloratadine, levocetirizine, loratadine and cetirizine are available in syrup 
formulations. 
•	 The metabolism of cetirizine in children is different to that in adults; hence, this 
drug should be taken twice daily.
•	 First-generation sedating antihistamines should be avoided due to the risk of 
psychomotor impairment, impacting on the child’s safety and education. Those 
licensed for use in childhood include diphenhydramine, hydroxyzine, promethazine 
and chlorphenamine.




Increase dose up to 3-4 X licensed dose 
of second-generation H1 antihistamines
3rd line
Add on to second line*: Omalizumab or 
Ciclosporin A or Montelukast
Short course (max 10 days) of oral 
corticosteroids for exacerbations if needed
Figure 1: The EAACI/GA2LEN/EDF/WAO (2013 revision and update)  
recommended treatment algorithm for urticaria6




after 1–4 further weeks
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